Recent Updates
Recently added Catalysts
ANTX Positive Sentiment

AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights

Monday, November 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: AN2 Therapeutics reported its third quarter financial results for 2026, highlighting significant advancements in its clinical pipeline. The company emphasized ongoing execution and progress in expanding opportunities within its boron chemistry platform. These developments reflect the company's commitment to innovation in small molecule therapeutics.

Market Sentiment Analysis

POSITIVE FACTORS

  • Continued execution across clinical pipeline.
  • Meaningful progress in business and scientific areas.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+34%
120-day peak, hindsight
Typical move
2.3%
average across 5 past catalysts
Cash runway
~31 mo
Low dilution risk
Lead asset
Epetraborole
Phase 2 · Polycythemia Vera (SNOMED CT: 109992005)

Full Press Release Details

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the third quarter ended September 30, 2026 and recent business and scientific highlights. “The third quarter was marked by continued execution across our clinical pipeline and meaningful progress in expanding the opportuni

Frequently Asked Questions

What did AN2 Therapeutics report for Q3 2026?

AN2 Therapeutics reported its financial results and progress in its clinical pipeline.

What is AN2 Therapeutics focused on?

The company focuses on developing novel small molecule therapeutics.

When did AN2 Therapeutics end its third quarter?

The third quarter ended on September 30, 2026.

What platform does AN2 Therapeutics use?

AN2 Therapeutics uses a boron chemistry platform for its therapeutics.

ShareAdd on Google
Tags: ANTX AN2 Therapeutics financial results clinical pipeline boron chemistry
Last updated: Nov 9, 2026

Biotech snapshot

Cash runway
$80M liquidity · $2M/mo burn
~31 mo
Low dilution risk
Lead asset
EpetraborolePhase 2
Polycythemia Vera (SNOMED CT: 109992005) →

Catalyst track record

+34%
best trade around ANTX's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ANTX.

See every catalyst's timing & PoA →